Article

Olive Oil and Soybean Oil Based Intravenous Lipid Emulsions, Liver Biochemistry and Clinical Outcomes

Fabio Araujo 1, Tanis R. Fenton 1,2,3*, Sara Lukmanji 3 and Maitreyi Raman 3,*

1 Department of Nutrition Services, Alberta Health Services, 3500 26 Ave NE, Calgary, AB T1Y 6J4, Canada; fabio.araujo@albertahealthservices.ca (F.A.); tfenton@ucalgary.ca (T.R.F.)
2 Community Health Sciences, Institute of Public Health, G055 3330 Hospital Drive, Calgary, AB T2N 4N1, Canada
3 Faculty of Medicine, University of Calgary, G055 3330 Hospital Drive, Calgary, AB T2N 4N1, Canada; sara.lukmanji@ucalgary.ca
* Correspondence: mkothand@ucalgary.ca; Tel.: +1-403-592-5020

Received: 3 April 2018; Accepted: 17 May 2018; Published: 23 May 2018

Abstract: Intravenous lipid emulsions are an essential component of parenteral nutrition (PN). Omega-6 reducing strategies may improve outcomes, including reduced PN associated liver disease, however evidence to support this recommendation is insufficient. The primary objective was to compare serum alkaline phosphatase (ALP), among patients provided with either soybean oil (Intralipid) or predominantly olive oil (Clinoleic) lipid emulsions. In this quasi-experimental study, we reviewed the medical records of surgical and medical adult patients who received lipid emulsions for at least seven consecutive days. Among the 206 patients (110—Intralipid, 96—Clinoleic) there was no significant difference in ALP and remaining liver function tests within 2 weeks of PN therapy initiation between groups, even after control for lipid doses. Macronutrient dosing was similar. Triglyceride level was higher by 0.7 mmol/L in the Clinoleic group; confidence interval 0.21 to 1.1; \( p = 0.004 \). The 30-day mortality, length of hospital stay, and proportion of patients admitted to intensive care were not significantly different. The Clinoleic group had a higher infection rate (36% vs. 22%, \( p = 0.031 \)) and longer intensive care stays (\( p = 0.045 \)). Well-designed randomized clinical trials comparing these lipid emulsions are necessary to confirm Intralipid superiority over Clinoleic in relation to infections and serum triglycerides.

Keywords: IV lipid emulsion; olive oil; parenteral nutrition; soybean oil; Intralipid; Clinoleic

1. Introduction

Intravenous lipid emulsions (IVLE) are essential components of parenteral nutrition (PN) solutions, providing energy and essential fatty acids. Soybean oil based IVLE Intralipid (20% Intralipid, Fresenius Kabi, Uppsala, Sweden) has been the staple IVLE in North America for PN therapy [1,2]. It is rich in the polyunsaturated fatty acid linoleic acid (n-6 PUFA) (52%), which functions as a precursor of arachidonic acid, giving rise to eicosanoids that may predispose a more pro-inflammatory response, potentially adversely affecting immunologic cell functions [3,4].

PN-induced cholestasis is a description of the onset of liver disease in the context of administration of intravenous nutrition in patients with temporary or permanent intestinal failure. Other terms commonly used to describe the condition are PN-associated liver disease (PNALD), PN-associated cholestasis (PNAC), and intestinal failure-associated liver disease (IFALD) [5]. All three terms are often used interchangeably. Excess calories, high doses of n-6 PUFA, high dextrose doses and the phytosterol content of IVLE have been associated with PNALD in the adult population [6–13].

Nutrients 2018, 10, 658; doi:10.3390/nu10060658 www.mdpi.com/journal/nutrients
The pathogenesis of PNALD is complex and multifactorial, and associated with a decrease in bile flow, resulting in cholelithiasis and bacterial overgrowth leading to gut translocation of endotoxins into the portal circulation [14,15]. PNALD can present as mild liver enzymes elevation with resolution following discontinuing PN, in addition to cholestasis, steatosis and steatohepatitis [11]. Liver enzyme elevation can be observed as early as five days after PN start and may peak after 2–4 weeks [16–18].

Clinoleic (20% Clinoleic, Baxter Corporation, Mississauga, ON, Canada; oil composition: 80% olive oil, 20% soybean oil) is a novel IVLE rich in monounsaturated acid oleic acid (n-9 MUFA). Its effect on the immune system is incompletely understood. In vitro studies have shown that MUFA has a neutral effect on inflammation [18–20]. An n-9 MUFA rich emulsion could be less prone to lipid peroxidation since it has a single unsaturation and a higher content of antioxidant alpha-tocopherol (Table 1) [21].

**Table 1.** Composition of lipid emulsions used in the study.

|                          | Soybean Oil Lipid Emulsion (Intralipid 20%) | Olive Oil Lipid Emulsion (Clinoleic 20%) |
|--------------------------|-------------------------------------------|----------------------------------------|
| 1000 mL contains:        |                                           |                                        |
| Soybean oil              | 200 g                                     | 40 g                                   |
| Olive Oil                | 0                                         | 160 g                                  |
| Glycerol Anhydrous       | 22 g                                      | 22.5 g                                 |
| Egg phospholipids        | 12 g                                      | 12 g                                   |
| Water for injection q.s.ad| 1000 mL                                   | 1000 mL                                |
| Sodium Oleate            | -                                         | 0.3 g                                  |
| Alpha-tocopherol         | 9–14 mg                                   | 25–35 mg                               |
| Phytosterols             | 348 ± 33 mg                               | 327 ± 8 mg                             |

Fatty acid profile (%)
- Saturated: 15% for both
- Mono-unsaturated: 24% for both
- Poly-unsaturated: 61% for both
- Oleic Acid: 22% for both
- Linoleic Acid: 52% for both
- ω-Linolenic Acid: 8% for both
- Linoleic: ω-3 Linolenic: 7:1 for both

Clinoleic 20%: Product Monograph; Baxter Corporation: Deerfield, IL, USA, 2014. Intralipid 20%, Product Monograph; Fresenius Kabi AB: Hongkong, China, 2013.

Clinoleic may be a superior choice to Intralipid, however the existing human trial evidence is not clear. Most of the human randomized trials of Clinoleic emulsion have been conducted on preterm infants [22] and home PN patients [23]. There is only limited information available to inform the decision making regarding lipid choices between Intralipid and Clinoleic among adult surgical and medical patients who require PN in the short term. A randomized clinical trial of Clinoleic versus Intralipid found no difference in the outcomes assessed (glycemia, length of stay, nosocomial infection, acute renal failure, inflammation, or oxidative stress markers), but liver function tests were not reported [24]. While a few small studies have shown that a predominantly olive oil based IVLE is well tolerated and safe [24,25], the clinical relevance of this IVLE remains unclear based on observations in small randomized clinical trials.

Since limited data is available for the adult population reporting on the experience with olive oil based IVLE, we designed a quasi-experimental study to review our experience with Clinoleic compared to Intralipid. Given biological plausibility for lower risk of PNALD with Clinoleic use, we hypothesized that biliary tree serum enzymes would be lower in this group on the follow up blood work when compared to the Intralipid group. We used serum alkaline phosphatase (ALP) as a surrogate marker of cholestasis as this test is part of the standard pre-PN blood work in our hospitals. Our primary objective was to compare the impact of Intralipid and Clinoleic IVLE on serum ALP—pre-PN to after one week of PN (i.e., between day 8 to 16 post-PN initiation)—while
controlling for the ordered lipid dosing and baseline levels. Secondary objectives were to assess if there were differences between the IVLEs on the remaining liver function tests, lipid dosing, incidence of infectious complications, length of stay in hospital, and 30-day mortality.

2. Materials and Methods

This retrospective quasi-experimental chart review was conducted in three tertiary care hospitals in Calgary, AB, between 1 July 2012 to 30 June 2013 and 1 July 2014 to 30 June 2015. Standard soybean oil-based therapy, Intralipid, was the only available IVLE in Calgary, AB until July 2013, at which time predominantly olive oil Clinoleic was approved as an alternative in the hospital formulary, accounting for the dates chosen for the study. Ethics approval from the Conjoint Health Research and Ethics Board at the University of Calgary was obtained prior to the initiation of the study.

2.1. Study Population

Study patients included adult patients (age > 18 years old) admitted to hospital who received PN with Intralipid or Clinoleic IVLEs for at least seven consecutive days. Study exclusion criteria included baseline liver disease, home PN prior to admission, ALP and total bilirubin (TB) not available within 3 days prior to PN start as well as between days 8 to 16 post PN start, receipt of Diprivan 1% (Propofol-AstraZeneca Canada Inc., Mississauga, ON, Canada) during PN support period, enteral nutrition providing greater than 600 Kcal daily for longer than half of time period on PN, and/or oral intake of greater than 50% of hospital meal tray contents for longer than half of the PN support time period. Enteral and oral intake data, documented by nursing staff, were collected from medical charts’ flow sheets.

2.2. Study Outcome Measures

The pre-declared primary outcome variable was the difference between groups’ serum ALP levels, 8 to 16 days after PN initiation of either Intralipid or Clinoleic IVLE. Pre-declared secondary outcome measures included comparing the (a) differences in serum levels of alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), TB, bilirubin direct (BD), and triglycerides (TG) measured between day 8 to 16; (b) dosing of IVLE prescriptions from days 3 to 16 (presuming that it takes 2 days to reach goal dose of PN and macronutrients); (c) all-cause mortality by 30 days; (d) length of hospital stay; and (e) infectious complications incidence during period on PN, defined as (i) positive sputum cultures plus characteristic chest X-ray findings of lobar consolidation or diffuse bilateral infiltrates requiring antibiotic therapy (pneumonia); (ii) catheter and blood revealing the same microorganism (catheter infection); (iii) positive peripheral blood cultures alone, and no other source identified (bacteremia); (iv) positive urine cultures requiring antibiotics (urinary tract infection) and/or (v) positive stool cultures. Analyses that were not pre-specified were not conducted. New infectious events were recorded from the second day of PN until the day after PN discontinuation. Each new infection was recorded once for each patient, even if there was more than one sample with positive microbiology culture. Catheter related infections were confirmed if there was the presence of the microorganism isolated from the catheter, concomitant with peripheral positive cultures. An infectious episode was considered non-catheter related if another source was confirmed positive with same microorganism identified in the peripheral culture only.

2.3. Statistical Analyses

Descriptive statistics, specifically proportions or means with standard deviations, were used to describe participants’ demographic characteristics, anthropometrics, and relevant medical history (i.e., diagnosis on admission, surgical history and indication for PN). Differences between the Intralipid and Clinoleic groups were analyzed using the t-test for continuous variables and Fisher’s Exact Test for the categorical variables. Multivariable linear regression analyses were undertaken to test for differences in the change from baseline laboratory values between lipid groups. A priori we planned to control
for variables that differed between the groups with \( p \)-values < 0.10 and baseline levels. Lipid doses ordered during the period on PN differed between the groups \( (p = 0.018) \), so were also controlled for.

Based on our sample size calculation that assumed an alpha of 0.05, power of 80\%, and a standard deviation of 15 units \[24\], we estimated the need for 120 patients in each group to identify a difference in ALP of 30 units/L. Further, using the aforementioned alpha and power, and assuming a standard deviation of 0.2 g/kg/day \[26\], we estimated 64 patients in each group were required to determine a difference in lipid ordering practices.

3. Results

Of the 1090 patient charts which were reviewed, 206 patients (110 in the Intralipid and 96 in the Clinoleic groups) met the inclusion criteria (Figure 1). The main reasons for non-inclusion in the study were lack of serum biochemistry values at the time of follow up (51\%) and total PN for less than 7 days (28\%) (Figure 1). Baseline patient characteristics between both groups of patients were similar (Table 2). Gastrointestinal illness or surgery were the primary indications for PN. There were no significant differences observed between the two groups for age, sex, BMI, nutrition status, diagnoses, or PN indications.

![Figure 1. Screening, inclusion and exclusion criteria.](image-url)
Table 2. Characteristics of patients.

|                       | Soybean Oil Based Intralipid<sup>a</sup> | Olive Oil Based Clinoleic<sup>b</sup> | p-Value |
|-----------------------|-----------------------------------------|--------------------------------------|---------|
| Number of patients    | 110                                     | 96                                   |         |
| Mean age (years) *    | 63.6 ± 14.3                             | 63.6 ± 15.8                          | 0.93    |
| Male                  | 48% (53/110)                            | 50% (48/96)                          | 0.89    |
| Mean weight (Kg)      | 71.7 ± 20.2                             | 75.2 ± 26                            | 0.24    |
| Mean BMI (Kg/m<sup>2</sup>) * | 27.3 ± 20.7                        | 26.8 ± 7.9                           | 0.84    |
| Nutrition Status (%/patients) | | | |
| Well Nourished        | 4% (4)                                  | 4% (4)                               |         |
| Mild or moderate malnutrition | 14% (15)                      | 15% (14)                             | 0.15    |
| Severe malnutrition   | 19% (21)                                | 7% (7)                               |         |
| Not reported          | 63% (70)                                | 74% (71)                             |         |
| Diagnosis on admission | | | |
| GI related conditions—Surgical | 44% (48/110)                        | 39% (37/96)                          |         |
| GI related conditions—Non Surgical | 8% (9/110)                       | 13% (12/96)                          |         |
| Cancer                | 33% (36/110)                            | 36% (35/96)                          |         |
| Pancreatitis          | 5% (6/110)                              | 5% (5/96)                            | 0.66    |
| Cachexia/Malnutrition | 2% (2/110)                              | 3% (3/96)                            |         |
| Other                 | 8% (9/110)                              | 4% (4/96)                            |         |
| Total surgical patients (GI + non GI) | 74% (81/110)                  | 79% (76/96)                          |         |
| Indication for TPN    | | | |
| GI related Conditions | 53% (58/110)                            | 62% (59/96)                          |         |
| Unsuccessful PO or EN | 20% (22/110)                           | 12% (11/96)                          |         |
| Reus                  | 8% (9/110)                              | 7% (7/96)                            | 0.68    |
| Pancreatitis          | 4.5% (5/110)                            | 5% (5/96)                            |         |
| Pre-op Boost          | 4.5% (5/110)                            | 4% (4/96)                            |         |
| Non-specified         | 10% (11/110)                            | 10% (10/96)                          |         |
| Parenteral Nutrition days 3–16 | | | |
| Energy (Kcal/Kg)      | 27.7 ± 4.4                              | 27.4 ± 4.3                           | 0.54    |
| Lipid dosing (g/Kg)   | 0.78 ± 0.11                             | 0.83 ± 0.16                          | 0.018   |
| Amino Acid dosing (g/Kg) | 1.5 ± 0.3                        | 1.6 ± 0.3                            | 0.07    |
| Dextrose dosing (g/Kg) | 4.0 ± 0.9                        | 3.7 ± 0.82                           | 0.010   |

* Plus-minus values are means ± standard deviation.

3.1. Primary Outcome

There was no significant difference in ALP levels between the IVLE groups after 2 weeks of PN (Table 3). In the multivariable model controlled for the dosing of lipid and baseline levels, the change in ALP from baseline was not associated with IVLE type (Table 3) or dosing of lipid.

Parenteral Nutrition Dosing

Total PN energy and amino acid delivered in both groups were similar. Lipid dosing was statistically significantly higher (0.83 vs. 0.78 g/Kg) and dextrose dosing was significantly lower (3.7 vs. 4.0 g/Kg) in patients receiving Clinoleic compared to Intralipid (Table 2).

3.2. Secondary Outcomes

Secondary outcomes are detailed in Tables 3 and 4. In the simple analysis, follow up levels of the remaining laboratory markers (ALT, GGT, TB, and BD) were not significantly different between the groups receiving the two types of lipid, except for TG, which were higher in the patients that received Clinoleic compared to the group that received Intralipid by 0.67 mmol/L, confidence interval 0.21 to 1.1 (p = 0.004, Table 3). In the multivariable models controlled for ordered lipid doses and baseline levels, lipid type was associated with change of serum TG, which were higher in the Clinoleic group (p = 0.002, Table 3), but none of the other lab markers. The number of observations was low for changes in direct bilirubin and triglycerides (n = 14 and 75, respectively). Lipid dose was not statistically predictive of liver enzymes, bilirubin, or TG levels in the multivariable models (data not shown).
Table 3. Liver biochemistry, bilirubin, and serum triglycerides by lipid type, Intralipid® versus Clinoleic®, after 2 weeks of parenteral nutrition *.

| Laboratory                        | n  | Intralipid® | Clinoleic® | Average Difference | Confidence Interval | p-Value | n  | Average Difference | Confidence Interval | p-Value |
|-----------------------------------|----|-------------|------------|--------------------|----------------------|---------|----|--------------------|----------------------|---------|
| Alkaline phosphatase (U/L)        | 110, 96 | 160 ± 133   | 175 ± 178  | 14.5               | −28.4 to 57.5        | 0.51    | 206 | 23.0               | −7.3 to 53.4         | 0.14    |
| Gamma-glutamyl transferase (U/L)  | 46, 48  | 185 ± 379   | 144 ± 211  | −41.0              | −167 to 85.2         | 0.52    | 116 | 46.3               | −6.7 to 99           | 0.09    |
| Alanine aminotransferase, (U/L)   | 55, 53  | 36 ± 34     | 54 ± 72    | 18.3               | −3.1 to 39.8         | 0.09    | 204 | 54.4               | −9.0 to 114           | 0.07    |
| Bilirubin total, (umol/L)         | 110, 96 | 14 ± 26     | 14 ± 26    | 0.2                | −7.0 to 7.3          | 0.97    | 206 | −2.8               | −9.1 to 3.6           | 0.40    |
| Bilirubin direct, (umol/L)        | 24, 17  | 18 ± 25     | 23 ± 9.3   | 5.8                | −14 to 26            | 0.56    | 16  | −11.1              | −30 to 8.1            | 0.23    |
| Triglycerides, (mmol/L)           | 64, 57  | 1.3 ± 0.7   | 2.0 ± 1.7  | 0.67               | 0.21 to 1.1          | 0.004   | 75  | 0.74               | 0.28 to 1.20           | 0.002   |

* Plus-minus values are means ± standard deviation. Average differences and confidence intervals represent the difference between the means for Clinoleic® minus Intralipid®.

Table 4. Other outcomes *.

| Soybean Oil Based Intralipid® | Olive Oil Based Clinoleic® | p-Value |
|-------------------------------|----------------------------|---------|
| Total period on TPN (days)    | 25 ± 37                    | 21 ± 24 | 0.36    |
| Median (IQR)                  | 16 (12–25)                 | 14 (11–23) | 0.28    |
| Patients admitted to ICU      | 25% (28/110)               | 32% (31/96) | 0.045   |
| Length of Stay in ICU (days)  | 6 ± 7                      | 12 ± 14 | 0.15    |
| Length of stay in hospital (days) | 43 ± 49                  | 54 ± 63 | 0.53    |
| 30 day mortality              | 11% (12/110)               | 14% (14/96) | 0.031   |
| Incidence of infections       | 22% (24/110)               | 36% (35/96) | 0.23    |
| Infection complications:      | 40.7% (24/59)              | 59.3% (35/59) | 0.031   |
| Non-catheter related bacteremia | 5                        | 9       |         |
| Catheter related Sepsis       | 2                         | 5       |         |
| Urine (UTI)                   | 15                        | 19      |         |
| Positive Sputum + Radiographic Evidence of Pneumonia (Lung infections) | 1 | 6 |         |
| Stool (C. diff)               | 3                         | 1       |         |

* Plus-minus values are means ± standard deviation.
While the analyses—both the univariate and controlled for baseline levels and lipid doses—were not significantly different between the two lipids except for TG, there were differences between the univariate and controlled estimated differences (Table 3), which indicates that either or both of the controlled variables (baseline and ordered doses) influentially confounded the univariate uncontrolled analyses to some degree.

The incidence of all infectious complications were significantly lower in patients receiving Intralipid (22%) compared with Clinoleic (36%, \( p = 0.031 \)). The infections by type did not differ between the groups. The 30-day mortality and proportion of patients admitted to the ICU did not differ significantly between the groups (Table 4). The length of hospital stay did not differ between the groups but the length of ICU stay was shorter for the Intralipid group compared to the Clinoleic group (Table 4, \( p = 0.045 \)).

4. Discussion

Our short term quasi-experimental study revealed some differences: higher serum TG, higher rate of infections, and longer length of ICU stay for patients that received Clinoleic compared to those who received Intralipid IVLE. The higher serum TG level remained significantly higher after controlling for lipid dose and baseline TG levels. Liver biochemistry (ALP, ALT) and liver function measured by TB and BD were similar between medical and surgical acute inpatients on PN receiving Intralipid or Clinoleic IVLE 8–16 days after starting PN, even after controlling for lipid doses and baseline levels. Our Intralipid and Clinoleic groups were similar in terms of age, gender, weight status, BMI, type of diagnosis, type of indication for PN start, and whether they received clinically similar lipid dosing (0.78 g/Kg in the Intralipid group vs. 0.83 g/Kg in Clinoleic group).

The prescribed lipid doses in our study were conservative, potentially explaining the lack of difference between the groups. The conservative lipid prescribing practices infer caution exercised by the treating dietitian with both lipids, despite previous reports that doses of up to 1.2 g/Kg are safe and well tolerated [27] and despite the expected biologic rationale for superiority of olive oil compared with soybean oil based IVLE [26,28–30]. Our findings are consistent with findings by previous studies. A similar difference in infection rates (57% vs. 43%, difference = 14%) to our study (36% vs. 22%, difference = 14%) was seen in a randomized clinical trial of Clinoleic or Intralipid in medical-surgical patients [24]. A subgroup analysis from a systematic review of critical care patients revealed non-significantly higher rates of infection among patients receiving olive oil based IVLE compared to long-and-medium-chain-triglyceride mixtures (RR = 1.23, 95% CI 0.92, 1.63, \( p = 0.16 \), heterogeneity \( I^2 = 0\% \)) [31]. Conversely, in a randomized controlled study with surgical adult patients (which differed by the PN delivery system (3-chamber system vs. lipids separate) and electrolyte dosing (standard dosing vs. custom prescription) as well as differing in IVLE) [25], patients receiving olive oil based IVLE experienced significantly fewer overall infections and higher albumin and pre-albumin compared with patients receiving Intralipid. In a separate non-randomized trial, no differences in catheter infections were observed along with ALT and TB between patients matched on age and gender after seven days of PN with either soybean or olive oil based IVLE post abdominal surgery, however ALP was significantly higher in the olive oil-based emulsion group [32].

Whether the higher observed infection rates in the Clinoleic group in our study are due to the lipids or confounding by group differences is not readily apparent. The baseline characteristics for patients in both groups were similar, and likely not contributory to this finding. The differences in infection rates between the groups were not due to the duration of PN, which was not statistically or clinically different between the two. The mean dextrose dosing was lower in the olive oil based IVLE group, and thus could not be implicated in contributing toward the higher infectious rates. Lipid doses were clinically similar. Umpierrez and colleagues [24] demonstrated that in a cohort of adult ICU patients, there were no differences in systemic inflammatory markers, oxidative stress, or immune markers between Clinoleic and Intralipid. These similar pathophysiologic mechanisms could explain the lack of superiority of Clinoleic over Intralipid regarding infectious outcomes, but does not
explain the increased infectious rates observed in this study. Larger well-designed randomized trials are needed to determine whether this finding is due to the different lipid infusions or due to chance or confounding by differences between our groups.

There are a few limitations in our study. This is a retrospective observational study where the subjects in different time periods were not randomized to the two lipid types. The differences in infections, length of ICU stay, and TG levels may be due to other factors that may have differed between the groups and time periods, such as disease etiology, disease severity, and comorbidities. We did not capture data on blood sugars, nor did we identify the proportion of patients with diabetes within each group. Poorly controlled blood sugars can have a substantial impact on the rates of infection. Despite similar baseline demographic and PN characteristics, individual patients and clinical course may be different, potentially explaining some study findings. Conceivably, the longer ICU and hospitalization of the cohort that received Clinoleic may reflect a sicker patient population.

5. Conclusions

Our study did not show statistically significant differences between Intralipid and Clinoleic IVLE in terms of liver enzymes, liver function tests, and length of stay in hospital or mortality. We observed a higher infection incidence in the Clinoleic group, however that did not lead to higher mortality rate. Serum TG and ICU length of stay were higher in the patients on Clinoleic compared to Intralipid. These findings should be considered hypothesis generating, rather than definitive results as they were from an observational study, and well-designed large randomized controlled trials are needed to better elucidate the impact of frequently used IVLEs on patient outcomes.

Author Contributions: F.A., M.R. and T.R.F. equally contributed to the conception and design of the research; T.R.F. contributed to the analysis of data. S.L. collected the study data. F.A., T.R.F. and M.R. contributed to the interpretation of the data and critically revised the manuscript. F.A. wrote the manuscript first draft. All authors, agree to be fully accountable for ensuring the integrity and accuracy of the work, and read and approved the final manuscript.

Acknowledgments: Funding for the study was provided by Baxter.

Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

References
1. Wretlind, A. Invited Review: Development of Fat Emulsions. J. Parenter. Enter. Nutr. 1981, 5, 230–235. [CrossRef] [PubMed]
2. Vassilyadi, F.; Panteliadou, A.-K.; Panteliadis, C. Hallmarks in the history of enteral and parenteral nutrition: From antiquity to the 20th century. Nutr. Clin. Pract. 2013, 28, 209–217. [CrossRef] [PubMed]
3. Calder, P.C.; Albers, R.; Antoine, J.-M.; Blum, S.; Bourdet-Sicard, R.; Ferns, G.A.; Folkerts, G.; Friedmann, P.S.; Frost, G.S.; Guarner, F.; et al. Inflammatory disease processes and interactions with nutrition. Br. J. Nutr. 2009, 101, S1–S45. [CrossRef] [PubMed]
4. James, M.J.; Gibson, R.A.; Cleland, L.G. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am. J. Clin. Nutr. 2000, 71, 343S–348S. [CrossRef] [PubMed]
5. Beath, S.V.; Kelly, D.A. Total Parenteral Nutrition–Induced Cholestasis. Clin. Liver Dis. 2016, 20, 159–176. [CrossRef] [PubMed]
6. Grau, T.; Bonet, A.; Rubio, M.; Mateo, D.; Farré, M.; Acosta, J.A.; Blesa, A.; Montejo, J.C.; de Lorenzo, A.G.; Mesejo, A.; et al. Liver dysfunction associated with artificial nutrition in critically ill patients. Crit. Care 2007, 11, R10. [CrossRef] [PubMed]
7. Allardyce, D.B. Cholestasis caused by lipid emulsions. Surg. Gynecol. Obstet. 1982, 154, 641–647. [PubMed]
8. Salvian, A.J.; Allardyce, D.B. Impaired bilirubin secretion during total parenteral nutrition. J. Surg. Res. 1980, 28, 547–555. [CrossRef]
9. Buchmiller, C.E.; Kleimanwexler, R.L.; Ephgrave, K.S.; Booth, B.; Hensley, C.E. Liver dysfunction and energy-source: Results of a randomized clinical-trial. *J. Parenter. Enter. Nutr.* 1993, 17, 301–306. [CrossRef] [PubMed]

10. Meguid, M.M.; Schimmel, E.; Johnson, W.C.; Meguid, V.; Lowell, B.C.; Bourinski, J.; Nabseth, D.C. Reduced metabolic complications in total parenteral nutrition: Pilot study using fat to replace one-third of glucose calories. *JPEN J. Parenter. Enter. Nutr.* 1982, 6, 304–307. [CrossRef] [PubMed]

11. Sheldon, G.F.; Peterson, S.R.; Sanders, R. Hepatic dysfunction during hyperalimentation. *Arch. Surg.* 1978, 113, 504–508. [CrossRef] [PubMed]

12. Zaloga, G.P. Phytosterols, Lipid Administration, and Liver Disease during Parenteral Nutrition. *JPEN J. Parenter. Enter. Nutr.* 2015, 39, 95–605. [CrossRef] [PubMed]

13. Zaman, N.; Tam, Y.K.; Jewel, L.D.; Coutts, R.T. Effects of intravenous lipid as a source of energy in parenteral nutrition associated hepatic dysfunction and lidocaine elimination: A study using isolated rat liver perfusion. *Bio Pharm. Drug Dispos.* 1997, 18, 803–819. [CrossRef]

14. Siddique, A.; Kowdley, K.V. Approach to a patient with elevated serum alkaline phosphatase. *Clin. Liver Dis.* 2012, 16, 199–229. [CrossRef] [PubMed]

15. Raman, M.; Almutairdi, A.; Mulesa, L.; Alberda, C.; Beattie, C.; Gramlich, L. Parenteral Nutrition and Lipids. *Nutrients* 2017, 9, 388. [CrossRef] [PubMed]

16. Grant, J.P.; Cox, C.E.; Kleinman, L.M.; Maher, M.M.; Pittman, M.A.; Tangrea, J.A.; Bro, J.H.; Gross, E.; Beazley, R.M.; Jones, R.S. Serum hepatic enzyme and bilirubin elevations during parenteral nutrition. *Surg. Gynecol. Obstet.* 1977, 145, 573–580. [PubMed]

17. Leaseburge, L.A.; Winn, N.J.; Schloerb, P.R. Liver test alterations with total parenteral nutrition and nutritional status. *J. Parenter. Enter. Nutr.* 1992, 16, 348–352. [CrossRef] [PubMed]

18. Buenestado, A.; Cortijo, J.; Sanz, M.J.; Yafa, N.-A.-N.; Magdalena, M.L.; Mata, M.; Issekutz, A.C.; Marti-Bonmati, E.; Morcillo, E.J. Olive oil-based lipid emulsion's neutral effects on neutrophil functions and leukocyte-endothelial cell interactions. *J. Parenter. Enter. Nutr.* 2006, 30, 286–296. [CrossRef] [PubMed]

19. Granato, D.; Blum, S.; Rössle, C.; Le Boucher, J.; Malnoë, A.; Dutot, G. Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. *JPEN J. Parenter. Enter. Nutr.* 2009, 24, 113–118. [CrossRef] [PubMed]

20. Reimund, J.-M.; Scheer, O.; Muller, C.D.; Pinna, G.; Duclos, B.; Baumann, R. In vitro modulation of inflammatory cytokine production by three lipid emulsions with different fatty acid compositions. *Clin. Nutr.* 2004, 23, 1324–1332. [CrossRef] [PubMed]

21. Wanten, G.; Beunk, J.; Naber, A.; Swinkels, D. Tocopherol isoforms in parenteral lipid emulsions and neutrophil activation. *Clin. Nutr.* 2002, 21, 417–422. [CrossRef] [PubMed]

22. Kapoor, V.; Glover, R.; Malviya, M.N. Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants. *Cochrane Database Syst. Rev.* 2015, 2, CD009172. [CrossRef] [PubMed]

23. Jones, C.J.; Calder, P.C. Influence of different intravenous lipid emulsions on fatty acid status and laboratory and clinical outcomes in adult patients receiving home parenteral nutrition: A systematic review. *Clin. Nutr.* 2018, 37, 285–291. [CrossRef] [PubMed]

24. Umpierrez, G.E.; Spiegelman, R.; Zhao, V.; Smiley, D.D.; Pinzon, I.; Griffith, D.P.; Peng, L.; Morris, T.; Luo, M.; Garcia, H.; et al. A double-blind, randomized clinical trial comparing soybean oil-based versus olive oil-based lipid emulsions in adult medical-surgical intensive care unit patients requiring parenteral nutrition. *Crit. Care Med.* 2012, 40, 1792–1798. [CrossRef] [PubMed]

25. Jia, Z.-Y.; Yang, J.; Xia, Y.; Tong, D.-N.; Zaloga, G.P.; Qin, H.-L. OliClinomel N4 Study Group Safety and efficacy of an olive oil-based triple-chamber bag for parenteral nutrition: A prospective, randomized, multi-center clinical trial in China. *Nutr. J.* 2015, 14, 119. [CrossRef] [PubMed]

26. Siqueira, J.; Smiley, D.; Newton, C.; Le, N.-A.; Gosmanov, A.R.; Spiegelman, R.; Peng, L.; Osteen, S.J.; Jones, D.P.; Quyychi, A.A.; et al. Substitution of standard soybean oil with olive oil-based lipid emulsion in parenteral nutrition: Comparison of vascular, metabolic, and inflammatory effects. *J. Clin. Endocrinol. Metab.* 2011, 96, 3207–3216. [CrossRef] [PubMed]

27. Cano, N.J.; Saingra, Y.; Dupuy, A.-M.; Lorec-Penet, A.-M.; Portugal, H.; Lairon, D.; Cristol, J.P.; Come, A.; Le Brun, A.; Atlan, P.; et al. Intradialytic parenteral nutrition: Comparison of olive oil versus soybean oil-based lipid emulsions. *Br. J. Nutr.* 2006, 95, 152–159. [CrossRef] [PubMed]
28. Waitzberg, D.L.; Lotierzo, P.H.; Logullo, A.F.; Torrinhas, R.S.; Pereira, C.C.; Meier, R. Parenteral lipid emulsions and phagocytic systems. *Br. J. Nutr.* **2002**, *87*, S49–S57. [CrossRef] [PubMed]

29. Palmblad, J.; Broström, O.; Lahnborg, G.; Udén, A.M.; Venizelos, N. Neutrophil functions during total parenteral nutrition and Intralipid infusion. *Am. J. Clin. Nutr.* **1982**, *35*, 1430–1436. [CrossRef] [PubMed]

30. Martínez, M.; Ballabriga, A. Effects of parenteral nutrition with high doses of linoleate on the developing human liver and brain. *Lipids* **1987**, *22*, 133–138. [CrossRef] [PubMed]

31. Manzanares, W.; Dhaliwal, R.; Jurewitsch, B.; Stapleton, R.D.; Jeejeebhoy, K.N.; Heyland, D.K. Alternative lipid emulsions in the critically ill: A systematic review of the evidence. *Intensive Care Med.* **2013**, *39*, 1683–1694. [CrossRef] [PubMed]

32. Onar, P.; Yildiz, B.D.; Yildiz, E.A.; Besler, T.; Abbasoglu, O. Olive oil-based fat emulsion versus soy oil-based fat emulsion in abdominal oncologic surgery. *Nutr. Clin. Pract.* **2011**, *26*, 61–65. [CrossRef] [PubMed]